Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein S100-A8/S100-A9 complex, commonly known as calprotectin, is a calcium- and zinc-binding heterodimer primarily expressed in the cytoplasm of neutrophils and monocytes. Upon activation or tissue damage, it is secreted into the extracellular space where it acts as a damage-associated molecular pattern (DAMP) or alarmin. Extracellular calprotectin binds to pattern recognition receptors, including Toll-like receptor 4 (TLR4) and the receptor for advanced glycation end products (RAGE), triggering downstream NF-kB and MAPK signaling cascades that amplify inflammatory responses and recruit immune cells. Additionally, calprotectin plays a key role in nutritional immunity by chelating essential transition metals (such as zinc and manganese) to starve invading pathogens. In pathological contexts, elevated levels of S100A8/S100A9 are associated with chronic inflammatory diseases (such as rheumatoid arthritis and inflammatory bowel disease), cardiovascular disorders, and various cancers, where it promotes tumor progression, metastasis, and immunosuppression within the microenvironment. Consequently, S100A8/S100A9 is a valuable diagnostic and prognostic biomarker, as well as an emerging therapeutic target. Small-molecule inhibitors, such as tasquinimod and paquinimod, are being developed to block its receptor interactions and mitigate pathological inflammation and tumor growth.
Binds to S100A9 or the S100A8/S100A9 complex to block its interaction with pattern recognition receptors such as Toll-like receptor 4 (TLR4), receptor for advanced glycation end products (RAGE), and EMMPRIN (CD147), thereby inhibiting downstream NF-kB and MAPK signaling pathways and reducing pro-inflammatory cytokine release.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein S100-A8/S100-A9 complex (Calprotectin) (S100A8/S100A9).